GOP Sen. Johnson investigating FDA rare disease drug rejections
WASHINGTON — Sen. Ron Johnson (R-Wis.) said he is investigating the Food and Drug Administration’s rejections of rare disease…
How Hims has transformed medicine in a few short years
As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front…
FDA offers clues to AI regulation with RecovryAI designation
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Why clinical trials on nutritional supplements are hard to design
Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising everything…
Digital twins in health care: Promising technology still years away
Two decades ago, futurist Ray Kurzweil laid out a bold vision for next-generation medicine in his book “The…
FDA’s Høeg plans to scrutinize SSRIs, RSV shots for babies
WASHINGTON — Tracy Beth Høeg, the top drug regulator at the Food and Drug Administration, indicated in her…
FDA reverses course, agrees to review Moderna’s flu vaccine
WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for…
We’re reading about China’s GLP-1 drugs, a puzzling FDA rejection
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding…
Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs…
Hims & Hers compounder received FDA warning letter| STAT
The Food and Drug Administration late last year issued a warning letter to MedisourceRx, a compounding pharmacy owned…
Marty Makary addresses staff concerns over drug voucher program
WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…